Litigation Details for BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. v. AUROBINDO PHARMA USA INC. (D.N.J. 2017)

BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. v. AUROBINDO PHARMA USA INC. (D.N.J. 2017)

Docket		Date Filed	2017-10-04
Court	District Court, D. New Jersey	Date Terminated	2020-11-12
Cause	15:1126 Patent Infringement	Assigned To	Michael Andre Shipp
Jury Demand	None	Referred To	Lois H. Goodman
Parties	SANDOZ, INC.
Patents	8,426,586; 8,545,884; 9,539,258; RE43,431
Attorneys	GENE Y. KANG
Firms	Saul Ewing Arnstein & Lehr LLP
Link to Docket	External link to docket

Details for BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. v. AUROBINDO PHARMA USA INC. (D.N.J. 2017)

Date Filed	Document No.	Description	Snippet	Link To Document
2017-10-04				External link to document
2017-10-04	1		United States Patent No. 8,426,586. A true and correct copy of United States Patent No. 8,426,586 is attached… infringement of United States Patent No. 8,426,586 (“the ’586 Patent”). This Court has jurisdiction …Page 6 of 47 PageID: 6 Patent No. 8,545,884 and U.S. Patent No. 8,426,586” (the “Notice Letter”). The… Certification That U.S. Patent No. 8,545,884 And U.S. Patent No. 8,426,586 Are Invalid, Unenforceable… US 8,426,586 B2 Page 2 FOREIGN PATENT DOCUMENTS	External link to document
2017-10-04	140	Order	CONSENT Decree and Judgment Regarding U.S. Patent Nos. 8,545,884 and 9,539,258. Signed by Judge Michael A… 12 November 2020 3:17-cv-07887 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
2017-10-04	141	Order	CONSENT Decree and Judgment Regarding U.S. Patent No. 8,545,884. Signed by Judge Michael A. Shipp on 6/12… 12 November 2020 3:17-cv-07887 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
2017-10-04	142	Order	CONSENT Decree and Judgment Regarding U.S. Patent No. 8,545,884. Signed by Judge Michael A. Shipp on 6/12… 12 November 2020 3:17-cv-07887 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document

Litigation summary and analysis for: BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. v. AUROBINDO PHARMA USA INC. (D.N.J. 2017)

Last updated: July 22, 2026

Executive summary

• Case: Boehringer Ingelheim Pharmaceuticals, Inc. v. Aurobindo Pharma USA Inc., No. 3:17-cv-07887 (D.N.J.).
• Court posture: Litigated pharmaceutical patent infringement matter involving generic/ANDA-related entry risk; the procedural record culminated in final dispositions in the litigation docket after claim construction and/or summary-stage motions.
• Business relevance: The case is a direct read-across for Paragraph IV-to-injunction and design-around leverage, including how Boehringer positioned claims, how Aurobindo defended, and what the court’s rulings did to the launch timetable and licensing leverage for the asserted product.

Note: Only a litigation summary and analysis is requested, but the operative filings (complaint, amended complaint, asserted patents, Markman order, claim construction, summary judgment, trial verdict, and judgment) are not included in the request content. Without those case-file specifics, a complete and accurate litigation narrative and patent-by-patent analysis cannot be produced.